Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Renzapride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 7/20 | 1.00 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 3/20 | 1.00 |
| ▸ | HTR3B known ✓ | O95264 | 3/20 | 1.00 |
| ▸ | HTR3D known ✓ | Q70Z44 | 3/20 | 1.00 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | HTR5A | P47898 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Renzapride SCHEMBL17037 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL678616 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5371909 | 0.99 | HTR3A (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5765864 | 0.99 | HTR3A (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5367707 | 0.99 | HTR3A (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5767174 | 0.98 | HTR3A (0.96) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5371617 | 0.98 | HTR3A (0.96) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL1650356 | 0.98 | HTR3A (0.96) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL8292934 | 0.89 | HTR3A (0.80) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL1047947 | 0.88 | HTR3A (0.78) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020035057-A1 | Treatment of movement disorders by administration of 5-hydroxytryptamine receptor/alpha2 adrenergic receptor antagonist compositions | RICHTER VIRGINIA PACT (US) | 2002-03-21 | — | — | US | claimed |
| EP-0239321-B1 | CHEMICAL COMPOUND | BEECHAM GROUP PLC (GB) | 1993-06-16 | — | — | EP | claimed |
| US-4975436-A | ADMINISTERING ENDO-E-AMINO-T-CHLORO-2-METHOXY-N-(1-AZABICYCLO-(3.3.1)-NON-4-YL)BENZAMIDE | GLAXO GROUP LIMITED (GB) | 1990-12-04 | — | — | US | claimed |
| US-4800225-A | Pharmacologically active hydrated azabicyclo compound | BEECHAM GROUP, P.L.C. (GB) | 1989-01-24 | — | — | US | claimed |
| EP-0239321-A2 | Chemical compound | BEECHAM GROUP PLC (GB) | 1987-09-30 | — | — | EP | claimed |
| US-20250213564-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEUROGENERATIVE DISEASE | THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4577305-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEUROGENERATIVE DISEASE | 1/1THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-07-02 | — | — | EP | disclosed |
| CN-119789869-A | Pharmaceutical composition | 嘉惟思远制药有限公司 | 2025-04-08 | — | — | CN | disclosed |
| US-12194031-B2 | Compounds for use in regulating follicle maturation | AARHUS UNIVERSITET (DK) | 2025-01-14 | — | — | US | disclosed |
| EP-4129285-B1 | COMPOUNDS FOR USE IN REGULATING FOLLICLE MATURATION | UNIV AARHUS (DK) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024218296-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| CN-117881405-A | Compositions and methods for improving vision | 阿祖拉眼科有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-5272168-A | Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents | SANDOZ LTD. (CH) | 1993-12-21 | — | — | US | disclosed |
| US-5225407-A | Cognition activators | GLAXO GROUP LIMITED (GB) | 1993-07-06 | — | — | US | disclosed |
| US-5198459-A | Carbazole compounds | SANDOZ LTD. (CH) | 1993-03-30 | — | — | US | disclosed |
| EP-0450757-A2 | Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood | GLAXO GROUP LIMITED (GB) | 1991-10-09 | — | — | EP | disclosed |
| US-5039680-A | Administering methyl-imidazole substituted carbazolone | SANDOZ LTD. (CH) | 1991-08-13 | — | — | US | disclosed |
| US-4975436-A | ADMINISTERING ENDO-E-AMINO-T-CHLORO-2-METHOXY-N-(1-AZABICYCLO-(3.3.1)-NON-4-YL)BENZAMIDE | GLAXO GROUP LIMITED (GB) | 1990-12-04 | — | — | US | disclosed |
| US-4883803-A | TROPANYL-INDOLE ESTERS | GLAXO GROUP LIMITED (GB) | 1989-11-28 | — | — | US | disclosed |
| EP-0302008-A2 | 5HT-3 antagonists for prevention of dependence | SANDOZ AG (CH) | 1989-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035057-A1 | Treatment of movement disorders by administration of 5-hydroxytryptamine receptor/alpha2 adrenergic receptor antagonist compositions | HTR2C, HTR2A, ADRA2C | HTR3A 8/4885HTR3E 28/4885HTR3B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.